As per this study the Global Recombinant Vaccine Market was valued USD XX MN (by revenue) in 2019 and is anticipated to reach USD XX MN by 2026 with a CAGR of XX%. By volume, the market was estimated XX KT in 2019 and is expected to reach XX KT by 2026 with a CAGR of XX%.
Recombinant vaccine refers to the biological suspension developed using recombinant DNA technology. The recombinant vaccine is produced by introducing genetic material of dead or attenuated antigen into the host body through a vector that results in stimulation of immune response. It is useful to offer resistance to malaria, typhoid, allergies, cancer, and various infectious diseases such as Ebola, Flu, HPV, measles, smallpox, etc.
Growing health threat on account of widespread of infectious diseases and increasing prevalence of cancer is driving the market growth. Rise in immunization programs by the government to promote resistant to diseases is further fueling the market demand. Ongoing advancement in the field of immunology, molecular biology, biochemistry, genomics, and proteomics is again boosting the market growth.
This detailed market study is centered on the data obtained from multiple sources and is analyzed using numerous tools including porter’s five forces analysis, market attractiveness analysis and value chain analysis. These tools are employed to gain insights of the potential value of the market facilitating the business strategists with the latest growth opportunities. Additionally, these tools also provide a detailed analysis of each application/product segment in the global market of recombinant vaccine.
The broad recombinant vaccine market has been sub-grouped into product and end-user. The report studies these subsets with respect to the geographical segmentation. The strategists can gain a detailed insight and devise appropriate strategies to target specific market. This detail will lead to a focused approach leading to identification of better opportunities.
- Subunit Recombinant Vaccine
- Attenuated Recombinant Vaccine
- Vector Recombinant Vaccine
- Recombinant Human Vaccine
- Animal Recombinant Vaccine
Furthermore, the report comprises of the geographical segmentation, which mainly focuses on current and forecast demand for recombinant vaccine in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The report further focuses on demand for individual application segments in all the regions.
Europe Recombinant Vaccine Market By Revenue (USD MN)
The report also covers detailed competitive landscape including company profiles of key players operating in the global market. The key players in the recombinant vaccine market include Bayer AG, Bharat Biotech, GlaxoSmithKline Plc., Green Cross Corporation, Merck & Co., Inc., Novartis AG, Pfizer Inc., Protein Science Corporation and Sanofi S A. among others. An in-depth view of the competitive outlook includes future capacities, key mergers & acquisitions, financial overview, partnerships, collaborations, new product launches, new product developments and other developments with information in terms of H.Q.
A combination of primary and secondary research has been used to determine the market estimates and forecasts. Sources used for secondary research include (but not limited to) Paid Data Sources, Company Websites, Technical Journals, Annual Reports, SEC Filings and various other industry publications. Specific details on methodology used for this report can be provided on demand.